Rosenbaum, Jerrold, MD

Psychiatrist-in-Chief, Massachusetts General Hospital,
Stanley Cobb Professor of Psychiatry, Harvard Medical School


Dr. Rosenbaum, Psychiatrist-in-Chief at the Massachusetts General Hospital and Stanley Cobb Professor of Psychiatry at Harvard Medical School, is recognized as one of the world’s authorities on mood and anxiety disorders, with a special emphasis on pharmacotherapy of those conditions. His research contributions include extensive leadership in the development of new therapies, the design and implementation of trials to develop innovative treatments for major depression, treatment resistant depression, and panic disorder, studies of psychopathology including comorbidity and subtypes, and studies of longitudinal course and outcomes of those disorders.

Dr. Rosenbaum has authored more than 400 original articles and reviews and has authored or edited 20 books. He currently serves on 12 editorial boards of professional journals or newsletters. A particular research focus has been ongoing studies of children at risk for anxiety disorders and depression, which examine behavioral differences, risk factors, longitudinal outcomes, treatment, genetics, and brain structure and function of children of parents with mood and anxiety disorders.

At Mass General, Dr. Rosenbaum directs a department of more than 600 clinicians, researchers, and trainees, named by U.S. News and World Report as the #1 Department of Psychiatry in the United States for 16 of the last 18 years. Also at Mass General – the largest hospital based research institution in the world, with over 700 million dollars per year of research funding – he served as Chair of the hospital’s Executive Committee on Research. His clinical and consulting practice specializes in treatment resistant mood and anxiety disorders, and he consults extensively to colleagues on management of these conditions.

Dr. Rosenbaum led the development of the Mass General outpatient service into a world leading clinical and clinical research center, with 45 specialty clinical and clinical research programs and over $60 million of annual external research funding. The Massachusetts General Psychiatry Academy, founded in 2005 with over 40,000 members, brings high quality, objective, and curriculum based continuing medical education to physicians and other health professionals across the nation and around the world. Dr. Rosenbaum was the 2007 recipient of the C. Charles Burlingame Award given annually for lifetime achievement in psychiatric research and education by the Institute of Living in Hartford, CT, and the 2011 Massachusetts Association of Mental Health Friend and Leader Award. He served as President and the Chairman of the Board of the Anxiety and Depression Association of America and is Vice President and on the Board for the American Foundation for Suicide Prevention. He also serves as a member of the MGH Board of Trustees. He and colleagues have recently founded a venture, PsyBrain, for the discovery and development of novel therapeutics for psychiatric disorders.

Dr. Rosenbaum received his undergraduate degree from Yale College and his medical degree from Yale School of Medicine. He completed his residency and fellowship in Psychiatry at Mass General, Harvard Medical School.


Senior Advisory Board
Equity Holdings
Medavante, Supernus
Last Updated: 9/20/2012

Privacy Statement

This website uses Echo360 technologies. Echo360 partners with the world’s leading educational institutions and industry associations to enhance the teaching and learning experience for students and professionals like you. Our goal is to enable a more engaging and successful learning experience by providing you with live and on-demand access to study tools, videos, and collaboration capabilities in an online classroom to help you achieve your educational goals. We believe you should always know what data we collect from you and how we use it. As part of our ongoing commitment to transparency, and to support new European data protection laws, we're updating our Privacy Policy to inform you about the information that you share with us.

The revised policy will take effect on May 25, 2018. By using our services on or after that date, you'll be agreeing to these updates. We encourage you to read this document in full.

Echo360, Inc. 11955 Freedom Drive, Suite 700, Reston, VA 20190 USA